Morgan Stanley Offers Quick Thoughts on Eloctate and Strategic Action Related to Baxter International

Loading...
Loading...
In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on
Baxter InternationalBAX
. In the report, Morgan Stanley noted, “MS biotech analyst Matthew Harrison's launch on the biotech sector shows Biogen Idec hemophilia projections consistent with our Baxter assumptions. Following recent clinical diligence, he estimates that long-acting penetration will reach nearly 30% globally by 2018. Diligence and survey work leaves him more confident in share gains relative to consensus, and he believes the first mover advantage is underappreciated by the Street, as discussed in his Biogen initiation, A lot More to Come, Initiate at Overweight (3/26/2014). Our Baxter model assumes 30-35% share loss in both the US and EU over the same time frame. Hemophilia competition remains a key risk for Baxter, but we see 3Q14 BAX 855 data as a bigger near-term mitigation event than the BIIB launch.” Baxter International closed on Wednesday at $70.08.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsDavid R. LewisMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...